- Reaction score
- 424
I posted whatever I managed in the biojapan thread Bros.
The RCI-02 device is most likely to improve regrowth results. I could believe that the device somehow has an impact on delays.
Not sure if it has received a CE marking yet.
Doesnt make sense, they could release data and commercialize much later. No problem.
Just a reminder, AHRS 2018 was held in Orlando, not Miami as shown aboveJust a reminder that Shiseido released this statement at a congress earlier in the year. If their trial for RCH-01 turned out to be bunk then there would be zero reason for them to release this.View attachment 101946
Just a reminder, AHRS 2018 was held in Orlando, not Miami as shown above
Just a reminder, AHRS 2018 was held in Orlando, not Miami as shown above
This was also my doubt why there is a mistake. But i cant find anything about an AHRS in Miami...
The device has little to do with it; the device is being targeted towards dermal injectables already in the market and Repcf's own skin products. It's just a highly precise injection device, which is useful when working on the face but has little utility for the scalp.
By “end of the year” he may have been referring to the end of this year.
How many pages of speculation posts is it going to take before everybody starts realizing everything should be taken with a grain of salt until officially announced?
I wish as hell that you are right !
No they don't need the device..but it may give improved results...that is the point.The compound needs to be injected, REPCF nor Shiseido never claimed that efficacy is dependent on the depth or precision of the injection. They conducted the trials before the built the device, so clearly they don't need the device to administer the compound. The device is for the face, where precision and depth IS very important, and there is a massive market for facial injectables, which is why REPCF is putting all its eggs in the device basket, as it will get them to cash positive quickly. The hair compound is in Shiseido's corner now - success or failure is dependent on them (and whether or not the compound actually works).
The only reason they will be going after new shareholders is to get more money.In February of 2014, Replicel shares were worth just over $9CAD a piece. Today, it closed it at $0.39.
I’m not entirely sure what to make of this, but it explains why they are aggresively going after new partnerships and shareholders.
https://www.sigmaaldrich.com/catalog/product/sigma/60205a?lang=it®ion=IT
Looks like you can buy dermal papilla cells… wat?
